[[{“value”:”
G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world.
The post Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos appeared first on MedCity News.
“}]]
